****Updated Jan 2011***

**MarketVIEW: Pseudomonas aeruginosa vaccines (CAT: VAMV010)**

Proposal No/#PO : [Enter client specific #PO]

Product Name : MarketVIEW: Pseudomonas aeruginosa vaccines – Global market forecast

Project Initiation Date : n/a

Billable days : n/a

Initiator(s) : [Enter client name, function and address]

Therapeutic Area : Nosocomial vaccines

Product (if applicable) : CAT No: VAMV010, updated January 2011

**Background**

Gram negative *Pseudomonas aeruginosa* (PA) is primarily a nosocomial pathogen accounting for around 10% of all hospital acquired infections second only to *Staphylococcus aureus*. PA infections are invasive and toxigenic and affect a wide variety of patient groups but mainly those with lung dysfunction such as pneumonia (ICU, ventilator assisted patients\(^1\)), COPD and Cystic fibrosis. Other important risk groups are severe burns patients.

Although PA infections are treatable, many forms of PA are multidrug resistant (MDR) and associated with high mortality. Despite previous failures of developmental prophylactic vaccines to prevent PA infections (Berna’s Aerugen) vaccine companies are now investigating newer strategies with the most advanced vaccine now in Phase II testing (IC-43, Intercell AG).

This MarketVIEW product is an Executive presentation and MS forecast model giving a comprehensive vaccine value ($USD/volume (000s) forecast of *Pseudomonas aeruginosa* vaccine within target nosocomial and lung disease populations until 2030 (global). The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targeting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.

---

\(^1\) Late-onset VAP – ventilator associated pneumonia
**Methodology**

Using currently available information regarding the profile and predicted deployment of *Pseudomonas aeruginosa* prophylactic vaccines, VacZine Analytics has modelled three potential global vaccine demand scenarios (mio doses) and revenue estimates ($000s) based upon detailed analysis of “at risk” target populations across major Western markets. The provided model also includes adjustable inputs of vaccine penetration, number of doses and pricing.

VacZine Analytics has closely monitored all significant source material pertaining to *Pseudomonas aeruginosa* epidemiology/vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the nosocomial field has also been utilised.

**PRODUCT CONTENTS:**

*Updated Jan 2011 (CAT No: VAMV010), PAGES: 30 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form*

****This product is composed of a model and summary presentation****

**Contents – Summary presentation (MS PowerPoint based)**

Author’s Note
Executive Summary
Pseudomonas vaccine – key model outputs
Pseudomonas vaccine total global predicted demand (doses, all scenarios)
Pseudomonas vaccine total global available market ($000s all scenarios)
Total global available market per country, base case ($000s)
ICU-MV patients, potential market ($000s) to 2030
Total available volume (doses) per vaccine segment, US – 2020
Total available value ($000s) per vaccine segment, US – 2020
Pseudomonas vaccine – key model assumptions
The role of *Pseudomonas aeruginosa* vaccine
Possible target populations for a Pseudomonas vaccine
How could a Pseudomonas vaccine be used in VAP?
Markets included in model
Population segments included in model: scenario definition
Population segments – low case
Population segments – base case
Population segments – hi case
Quantifying patient segments: at risk ICU
Quantifying patient segments: burns and cystic fibrosis
Quantifying patient segments: lung diseases
Quantifying patient segments: selected transplants
Major commercial model assumptions
Commercial model assumptions: US/Canada + Major EU
Commercial model assumptions: Major EU + other EU
Commercial model assumptions: Australia/Japan
Pricing: high level pharmacoeconomic analysis – ICU VAP
Pseudomonas vaccine – competitive environment
US economic burden of VAP and potential cost savings
Pseudomonas vaccines: competitive environment
Intercell Pseudomonas vaccine (IC-43)
IC-43: update October 2010
Intercell Pseudomonas vaccine (IC-43): estimated filing dates per indication
Pseudomonas monoclonal antibodies: clinical candidates
Background to ventilator associated pneumonia (VAP)
Risk factors for MDR pathogens causing HAP/VAP
Current management of VAP
Bibliography
Disclaimer
About VacZine Analytics

Contents – Vaccine demand model (MS Excel-based)

Title sheet
TOTAL CHARTS – forecast to 2030
CHARTS ICU-MV
CHARTS VALUE – HIGH
CHARTS VALUE – BASE
CHARTS VALUE – LO
CHARTS VOLUME – HIGH
CHARTS VOLUME – BASE
CHARTS VOLUME – LO
VALUE SUMMARY (TOTAL MARKET)
VOLUME SUMMARY (TOTAL MARKET)
VAL VOL SUMMARY (ICU-MV) only
US (all scenarios LO/BASE/HIGH)
Canada
UK
Germany
France
Spain
Italy
EU – other
Australia
Japan
Country target vaccine populations – forecast to 2030
Source material
Mechanical ventilations
CF Epidemiology
HESOnline (UK)
Transplants
Pricing analysis
Back page
About VacZine Analytics
Disclaimer

WORKSHEETS: 65
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $7995.00/ GBP £5395.00 (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

6. VacZine Analytics – internal analysis, 2010
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009